Even though POT1 seems to be the second major melanoma susceptibility gene, with 2%–4% of CDKN2A/CDK4-WT families carrying a pathogenic coding variant in this gene, its contribution to melanoma risk burden in the general population is minor, with ~0.5% of cases carrying pathogenic variants. This evidence concerns the gene CDK4 and melanoma.